Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Resected Mass Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy Sponsor:   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials